Genor Biopharma Holdings Ltd. has announced advancements in the clinical evaluation of GB261, a novel T-cell engager. Candid Therapeutics, Inc., the licensee of GB261, has initiated clinical trials targeting autoimmune diseases, with the first patients having been dosed and reportedly tolerating the treatment well. The company has also established a subcutaneous dosing formulation for GB261. This bispecific antibody is designed to target CD20 on B-cells and CD3 on T-cells, aiming to mediate cytotoxicity against CD20-expressing B-cells while minimizing excessive T-cell activation. A phase I/II open-label multi-center study for relapsed/refractory B-cell non-Hodgkin's lymphoma has been completed in China and Australia. There is no assurance provided regarding the successful development and marketing of GB261.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。